Lilly Shares Tumble Most In Years On Sagging Obesity Drug Demand
“Lilly’s shares plummet 7% as sagging demand for its obesity drug, Mounjaro, hurts sales. The company’s reliance on the medication, which has seen declining prescriptions, has investors reassessing its prospects #Lilly #Mounjaro”